NewEdge Wealth LLC Invests $27.51 Million in Medpace Holdings, Inc. $MEDP

NewEdge Wealth LLC acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 51,943 shares of the company’s stock, valued at approximately $27,508,000. NewEdge Wealth LLC owned about 0.19% of Medpace as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC purchased a new position in shares of Medpace in the 4th quarter worth about $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace during the 2nd quarter valued at about $31,000. Basecamp Wealth Advisors LLC increased its position in shares of Medpace by 187.5% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Medpace during the 2nd quarter valued at about $34,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the transaction, the director owned 12,275 shares in the company, valued at $7,430,916.75. The trade was a 8.50% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 67,195 shares of company stock worth $37,989,998. 20.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on MEDP shares. Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Truist Financial increased their target price on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Finally, Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $584.18.

Medpace Stock Performance

Shares of MEDP stock opened at $608.27 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a 50 day moving average price of $544.34 and a two-hundred day moving average price of $491.59. The company has a market capitalization of $16.98 billion, a P/E ratio of 35.65, a PEG ratio of 2.63 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the business earned $3.10 earnings per share. The business’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.